Area of research
Oncology · Pulmonary and Respiratory Medicine
Research interest
Research focused on Cancer research and Triple-negative breast cancer, with related work in Neutropenia, Apoptosis, Apatinib. Notable publications include 'Multicenter phase II study of Apatinib in non-triple-negative metastatic breast cancer', 'Exosomal annexin A6 induces gemcitabine resistance by inhibiting ubiquitination and degradation of EGFR in triple-negative breast cancer', and 'DNA damage response inhibitors: An avenue for TNBC treatment'.
Xerophenone H, a naturally-derived proteasome inhibitor, triggers apoptosis and paraptosis in lung cancer
PLEASURABLE: Results and biomarkers analysis from the phase II study of dalpiciclib combined with pyrotinib and endocrine therapy (ET) in women with dual-receptor positive (ER+/HER2+) metastatic breast cancer (MBC).
Exosomal annexin A6 induces gemcitabine resistance by inhibiting ubiquitination and degradation of EGFR in triple-negative breast cancer
DNA damage response inhibitors: An avenue for TNBC treatment
Advantages with prophylactic PEG-rhG-CSF versus rhG-CSF in breast cancer patients receiving multiple cycles of myelosuppressive chemotherapy: an open-label, randomized, multicenter phase III study
Multicenter phase II study of Apatinib in non-triple-negative metastatic breast cancer